Brief: Bausch Health Companies - FDA Approves Cabtreo(Tm) Topical Gel For Treatment Of Acne Vulgaris In Patients Twelve Years Of Age And Older
20/10/2023 22:31
Oct 20 (Reuters) - Bausch Health Companies Inc BHC.TO :
* BAUSCH HEALTH COMPANIES - FDA APPROVES CABTREO(TM) TOPICAL
GEL
FOR TREATMENT OF ACNE VULGARIS IN PATIENTS TWELVE YEARS OF AGE
AND OLDER
* BAUSCH HEALTH COMPANIES INC - CABTREO IS EXPECTED TO BE
AVAILABLE TO PATIENTS IN Q1 2024
Source text for Eikon: ID:
Further company coverage: BHC.TO
Recent news on Bausch Health Companies
See all newsCanada Stocks: TSX inches lower as tech and mining shares fall
Bausch Health Companies Inc. reports results for the quarter ended September 30 - Earnings Summary
Brief: Bausch Health Announces Full Redemption Of 8.500% Senior Notes Due 2027
Brief: Bausch Health Announces $50 Million Share Repurchase Program
Brief: Bausch Health Announces $50 Million Share Repurchase Program